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ABSTRACT 
A chromatographic system prominence consisting of quaternary solvent delivery pump, a degasser, an injector, column oven and photodiode array detector, 
LC 20AT series. C18 (4.6*250) mm, 5 micron column was used. The instrumental settings were a flow of 1ml/min. the injection volume was 20ul. The 
detection wavelength was 190 nm for all the three analytes 
Key words: Sulbactam and Cefoperazone, RP-HPLC, C18 (4.6*250) mm, 5 micron column, Validation. 
 
 INTRODUCTION 
Cefoperazone  (fig-I)  is  chemically  7-D(-)-(4-ETHYL-2,3-
DIOXO-1-PIPERZINE  Carboxamido)  (4-hydroxyphenyl) 
acetamido-3-(1-methyl)-1Htetrazol-5-yl)thiomethyl-3-cepham 
-carboxylic  acid.  Broad  spectrum  third  generation 
cephalosporin antibiotic
1, 2 Sulbactam (fig-I) is chemically (2s-
cis)-3,3-dimethyl-7-oxo-4-thiol-1-azabicyclo[3.2.0] heptane-2-
carboxylic  acid4,4-dioxide.  In  combination  with  β-lactam 
antibiotics it acts as an antibacterial
3-6. 
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Figure 1. The structure of Cefoperazone and Sulbactam . 
Cefoperazone 
 
Literature review indicated that HPLC methods have 
been reported for Cefoperazone and Sulbactam, combination 
in formulation whereas the reported methods are more time 
consuming  (12  min).  Since  the  selected  formulation  is  a 
multi-component system, rapid HPLC method was developed 
for the simultaneous estimation of these drugs in combined 
dosage forms with internal standard
7-10. 
MATERIALS AND METHODS 
Cefoperazone,Sulbactam  and  Ornidazole  standards  were 
obtained  from  Aurobindo  Laboratories,  Ltd.  (Hyderabad, 
India),methanol,  acetonitrile  and  phosphate  buffer(HPLC 
grade)  were  obtained  from  Qualigens  Fine  Chemicals 
(Mumbai, India). The (Ceftop) tablets (Ranbaxy laboratories) 
of  the  combination  of  sulbactam  and  cefoperazone  were 
purchased  commercially.  Double  distilled  water  was  used 
throughout the experiment. Other chemicals used were have 
analytical or HPLC grade. 
Chromatographic Conditions 
A  chromatographic  system  prominence  consisting  of 
quaternary  solvent  delivery  pump,  a  degasser,  an  column 
oven  and  photodiode  array  detector,  LC20-AT  series,  C18 
(4.6*250) mm, 5 micron column was used. The instrumental 
settings were a flow of 1Ml/min. The injection volume was 
20ul.The  detection  wavelength  was  190nm  for  all  three 
analytes. The peak purity was checked with the photodiode 
array detector from LC20-AT. 
Mobile  Phase-  The  mobile  phase  consisted  of  buffer  and 
acetonitrile in the ratio of 35:65(v/v). the pH of the mobile 
phase was adjusted to 20mM(v/v) of di potassium hydrogen 
ortho  phosphate  buffer  in  the  double  distilled  water.  The 
mobile phase was mixed and filtered through a nylon filter 
and degassed. 
Standard  stock  solution-  Standard  stock  solutions  were 
prepared by dissolving the drugs in the diluents and diluting 
them  to  the  desired  concentrations.  Diluent  used  for  the 
standards  and  sample  preparations  was  done  as  follows. 
Diluents were composed of water and acetonitrile in the ratio 
of  50:50(v/v)  and  diluents  b  was  composed  of  buffer  and 
acetonitrile in the ratio of 35:65(v/v). 
Preparation of Standard Solution: 
10 mg of Cefoperazone was taken in a 10 ml standard flask. 
To this 2 ml of mobile was added for dissolving the drug. 
Shake it for one min. to get a clear solution and make up the 
volume to 10 ml with mobile phase (stock solution A). 
10 mg of Sulbactam was taken in a 10 ml standard flask and 
diluted  with  few  ml  of  mobile  phase  until  the  sample 
dissolves completely and make up the volume to 10 ml with 
mobile phase (stock solution B). 
The internal standard solution was prepared by taking 10 mg 
of  ornidazole in a 10 ml standard flask. It is dissolved  by 
adding 3 ml of mobile phase, shake it for few minutes to get a 
clear solution and make up the final volume to 10 ml with 
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The final standard solution was prepared in such a way that 
each  standard  flask  contains  10,  20,  30,  40  and  50  mg  of 
cefoperazone and sulbactam and 20mg of ornidazole (IS). 
Preparation of Formulation Solutions: 
500 mg of each cefoperazone and sulbactam was dissolved 
then extracted with 50 ml of mobile phase (10mg/ml) . This 
was then filtered and diluted to 10 mg/ml of cefoperazone 
and sulbactam. From this, 2.5 ml of solution was drawn and 
mixed with 2 ml of internal standard so that these solutions 
when diluted to 10 ml with mobile phase contain 25 mg/ml of 
cefoperazone  and  sulbactam  and  20  mg/ml  of  internal 
standard. 
Calibration curve solutions- The calibration curve solution 
containing  5-140ug/ml  of  cefoperazone  and  5-140ug/ml 
sulbactum and 20ug/ml of ornidazole in each calibration level 
was prepared. 
RESULTS AND DISCUSSION  
Optimization of the chromatographic conditions 
Our objective of chromatographic method development was 
achieve  peak  tailing  factor<2,  retention  time  below  10 
minutes,  Along  with  resolution  between  Cefoperazone, 
Salbactam and internal standard (Ornidazole)>2. 
The  chromatographic  separation  was  achieved  using  C18 
(4.6*250)  mm,  5  micron  column.  The  chromatographic 
method  was  optimized  by  changing  the  composition  of 
mobile phase and pH of the mobile phase. 
Validation of the method 
The  accuracy  of  the  method  was  determined  by  recovery 
experiments. The recovery studies were carried out 6 times 
and the percentage recovery and percentage relative standard 
deviation  of  the  percentage  recovery  were  calculated  and 
presented in Table1. 
Drug 
  %  Recovery    % RSD 
50% level  100% level  50% level  100% 
level 
Sulbactam  98.8  100.71  0.2015  0.1811 
Cefoperazone  97.08  99.60  0.1492  0.2139 
Table1: Accuracy (Recovery Studies) 
The  precision  of  the  method  was  determined  by  studying 
repeatability and reproducibility. The response factor of drug 
peaks  and  percentage  relative  standard  deviation  were 
calculated and presented in Table.2&3. The results revealed 
that the method developed is reproducible. 
Repeatability of injection 
A standard solution of mixture of drugs was injected 6 times 
and its % RSD was calculated. 
Table2: Repeatability of injection 
  S= Sulbactam, C= Cefoperazone. 
The  response  factor,  slope,  intercept  and  correlation 
coefficient values were calculated. The correlation coefficient 
of Sulbactam and Cefoperazone were found to be 0.9994 and 
0.9998  respectively.  The  calibration  curves  were  plotted 
using  response  factor  Vs  concentration  of  the  standard 
solutions. The calibration graph shows that linear response 
was  obtained  over  the  range  of  concentrations  used  in  the 
assay procedure. These data demonstrates that the methods 
have adequate sensitivity to the concentration of the analytes. 
The range demonstrates that the method is linear outside the 
limits of expected use. 
The LOD and LOQ of the developed method were 
determined by analyzing progressively low concentration of 
the  standard  solutions  using  the  developed  methods.  The 
LOD is the smallest concentration of the analyte that gives a 
measurable  response  (signal  to  noise  ratio  of  3).  LOD  of 
Sulbactam, Cefoperazone and Ornidazole were found to be 
50, 50 and 100 ng/ml. the LOQ is the smallest concentration 
of the analyte, which gives response that can be accurately 
quantified  (signal  to  noise  ratio  of  10).  The  LOQ  of 
Sulbactam, Cefoperazone and Ornidazole were found to be 
300, 400 and 500 ng/ml. 
The  resolution,  capacity  factor,  theoretical 
plates/meter, peak symmetry was calculated for the standard 
solutions and is presented in Table. 3. The values obtained 
demonstrated the suitability of the system for the analysis of 
the above drug combination. 
Drug  Rs  N  K’  a a a a 
HET
P 
LOD
ng/m
l 
LOQng/ml 
Sulbactam  5.4
4 
3485
5 
0.33
4 
2.66
6 
28  50  300 
Cefoperazone  8.3
6 
3904
8 
0.89
6  25  50  400 
Table3: System suitability studies 
The recovery studies in plasma were carried out 3 
times  and  the  percentage  recovery  and  percentage  relative 
standard  deviations  of  the  percentage  recovery  were 
calculated. Among the 4 solvents 1% tri chloro acetic acid 
(TCA)  has  showed  good  recovery.  Acetonitrile  has  given 
good  recovery  (90.54%)for  Sulbactam  but  poor 
recovery(<30%)  for  Cefoperazone.  Where  as  in  the  rest  2 
solvents 1% H2So4 and di ethyl ether drugs recovery was not 
within  limits.  The  recovery  values  with  1%  TCA  were 
presented in Table4.  
S. 
No. 
Name  of  the 
Drug 
Amount 
added 
µg/ml 
Amount 
recovered 
µg/ml 
% 
Recovery  RSD 
1.  Sulbactam  50  42.35  84.7  0.13 
2.  Cefoperazone  50  40.28  80.56  0.71 
Table 4:  Recovery Studies 
Hence the developed method for the simultaneous estimation 
of Cefoperazone and Sulbactam in combined dosage forms is 
accurate, precise, linear, simple and rapid. 
Estimation 
Estimation of Cefoperazone and Sulbactam in dosage forms 
by  High  Performance  Liquid  Chromatography  was  carried 
out  using  optimized  chromatographic  conditions.  The 
standard  and  sample  solutions  were  prepared  and 
chromatograms were recorded.  
The peak area ratios of standard and sample solutions were 
calculated. The assay procedure was repeated for 6 times and 
mean  peak  area,  mean  peak  area  ratio,  mean  weight  of 
standard drugs, mean weight of sample taken for assay were 
calculated.  The  percentages  of  individual  drugs  found  in 
formulations, mean, and standard deviation in formulations 
were  calculated  and  presented  in  Table  5.  The  results  of 
Concentration 
(m m m mg/ml) 
Inject
ion 
Peak area  % RSD 
S  C  S  C 
Sulbactam 
(20 mg/ml) 
Cefoperazone 
(20 mg/ml) 
1  2120228  9051325 
.114
6 
.028
5 
2  2120822  9052672 
3  2121025  9051821 
4  2121186  9052461 
5  2121650  9051923 
6  2121382  9051627 Sharma Amit K. et al: Simultaneous HPLC Determination of Sulbactam and Cefoperazone 
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analysis  shows  that  the  amount  of  drugs  was  in  good 
agreement with the label claim of the formulation. 
Drug  Label Claim 
(mg/tablet) 
Estimated 
Amount 
(mg/tablet) 
%  Label 
claim  SD 
Sulbactam  500  498.992  99.7984  0.002 
Cefoperazone  500  489.578  97.9156  0.024 
Table5: Analysis of Formulation 
Determination of active ingredients in tablets 
The contents of two drugs in tablets were determined by the 
proposed method using the calibration curve. The results are 
shown in Table5. The chromatogram of the tablet sample is 
shown in (FigureII). 
 
Figure2.A  typical  chromatogram  of  the  tablet: 
Sulbactam(3.1), Cefoperazone(4.2),Ornidazole(5.9). 
SUMMARY AND CONCLUSION 
The scope and objective of the present work is to optimize 
the  chromatographic  conditions,  to  develop  HPLC  method 
for  the  estimation  of  drugs  in  selected  multi-component 
dosage form and the same is validated. 
Various  solvent  systems  were  tried  among  which  sodium 
phosphate buffer: Acetonitrile with ratio 65:35, pH 3.5 was 
selected  as  mobile  phase,  which  gave  good  resolution  and 
peak shapes. The flow rate was set at 1.0 ml/min. detection 
was carried out by PDA detector at 190 nm. Quantitation was 
done  by  internal  calibration  method.  At  the  optimum 
conditions  mentioned  above,  ornidazole  was  selected  as 
internal standard for the analysis. 
The  linearity  and  range  was  established  over  the 
range  of  5µg/ml  to  140  mg/ml  for  both  Cefoperazone  and 
Sulbactam. The correlation coefficient of Cefoperazone and 
Sulbactam were found to be 0.9994 and 0.9998. The method 
was validated for accuracy, precision, and system suitability. 
The percentage recovery of Cefoperazone and Sulbactam was 
found to be 98.8 % and 97.04 % for 50%level;100.7%, and 
99.6% for 100% level. The low standard deviation value and 
good  percentage  recovery  indicates  the  reproducibility  and 
accuracy of the developed method. Similarly the RSD value 
for precision was also within the acceptable limit.  
The  chromatographic  method  developed  for  Cefoperazone 
and Sulbactam is said to be rapid, simple, precise, accurate 
and cost effective that can be effectively applied for routine 
analysis in research institutions, quality control department in 
industries,  approved  testing  laboratories,  bio-pharmaceutics 
and bio-equivalence studies and in clinical pharmacokinetic 
studies. 
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